{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:14:35Z","timestamp":1790864075387,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.berh.2011.10.015","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T22:44:47Z","timestamp":1323384287000},"page":"665-681","source":"Crossref","is-referenced-by-count":27,"title":["Gaucher disease and bone"],"prefix":"10.1016","volume":"25","author":[{"given":"P.","family":"Mikosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2011.10.015_bib1","unstructured":"Gaucher P. De l' epithelioma primitive de la rate, hypertrophic idiopathique de la rate sans leucemie (doctoral thesis), Paris; 1882."},{"key":"10.1016\/j.berh.2011.10.015_bib2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10354-010-0814-1","article-title":"Laboratory and genetic evaluation of Gaucher disease","volume":"160","author":"Bodamer","year":"2010","journal-title":"Wien Med Wschr"},{"key":"10.1016\/j.berh.2011.10.015_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ejim.2006.07.005","article-title":"Epidemiology and natural history of Gaucher\u2019s disease","volume":"17","author":"Mehta","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.berh.2011.10.015_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10354-010-0850-x","article-title":"Neuropathic Gaucher disease","volume":"160","author":"Pastores","year":"2010","journal-title":"Wien Med Wschr"},{"key":"10.1016\/j.berh.2011.10.015_bib5","unstructured":"Walton-Bowen K, Mantick N. Gaucher registry annual aggregate data report; 2000."},{"key":"10.1016\/j.berh.2011.10.015_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.0009-9163.2004.00217.x","article-title":"Gaucher\u2019s disease: a paradigm for interventional genetics","volume":"65","author":"Germain","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.berh.2011.10.015_bib7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10354-010-0864-4","article-title":"The pathophysiology of GD \u2013 current understanding and rationale for existing and emerging therapeutic approaches","volume":"160","author":"Hughes","year":"2010","journal-title":"Wien Med Wschr"},{"key":"10.1016\/j.berh.2011.10.015_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","article-title":"An overview on bone manifestations in Gaucher disease","volume":"160","author":"Mikosch","year":"2010","journal-title":"Wien Med Wschr"},{"key":"10.1016\/j.berh.2011.10.015_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","article-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10","volume":"90","author":"Allen","year":"1997","journal-title":"QJM"},{"key":"10.1016\/j.berh.2011.10.015_bib10","first-page":"205","article-title":"Cytokines in Gaucher\u2019s disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.berh.2011.10.015_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","article-title":"Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease","volume":"23","author":"Hollak","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1442-200X.2007.02502.x","article-title":"Roles of specific cytokines in bone remodelling and hematopoisis in Gaucher disease","volume":"49","author":"Yoshino","year":"2007","journal-title":"Pediatr Int"},{"key":"10.1016\/j.berh.2011.10.015_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bcmd.1997.0156","article-title":"Cytokine mRNA in Gaucher disease","volume":"23","author":"Lichtenstein","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib14","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood-2009-02-205708","article-title":"Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome","volume":"114","author":"Campeau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.berh.2011.10.015_bib15","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)\u20131\u03b1 and MIP-1\u00df in the development of osteolytic in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.berh.2011.10.015_bib16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"Breemen","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.berh.2011.10.015_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/bcmd.1999.0237","article-title":"T cell numbers relate to bone involvement in Gaucher disease","volume":"25","author":"Lacerda","year":"1999","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10354-009-0647-y","article-title":"Pathophysiology of osteoporosis","volume":"159","author":"Sipos","year":"2009","journal-title":"Wien Med Wschr"},{"key":"10.1016\/j.berh.2011.10.015_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","article-title":"Skeletal complications of Gaucher disease","volume":"64","author":"Stowens","year":"1985","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2011.10.015_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","article-title":"Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease","volume":"28","author":"Drugan","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00223-001-2072-0","article-title":"Bone marker alterations in patients with type 1 Gaucher disease","volume":"72","author":"Ciana","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.berh.2011.10.015_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","article-title":"Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy","volume":"28","author":"Ciana","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerecyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.berh.2011.10.015_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","article-title":"Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy","volume":"28","author":"Schiffmann","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s774-002-8444-1","article-title":"Bone ultrasonometry, bone density, and bone turnover markers in type 1 Gaucher disease","volume":"20","author":"Fiore","year":"2002","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.berh.2011.10.015_bib26","first-page":"31","article-title":"Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase","volume":"13","author":"Parisi","year":"2008","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.berh.2011.10.015_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-008-9143-4","article-title":"Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat","volume":"83","author":"Mikosch","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.berh.2011.10.015_bib28","article-title":"Markers of bone turnover in Gaucher disease: Modeling the evolution of bone","volume":"May 4","author":"Dussen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2011.10.015_bib29","doi-asserted-by":"crossref","first-page":"19,473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.berh.2011.10.015_bib30","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V96.5.1969","article-title":"Pathologic gene expresion in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K","volume":"96","author":"Moran","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.berh.2011.10.015_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2006.05978.x","article-title":"Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease","volume":"133","author":"Magal","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.berh.2011.10.015_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","article-title":"Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry","volume":"96","author":"Mikosch","year":"2009","journal-title":"Mol Genet"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.10.015_bib33","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: a review","volume":"75","author":"Wentrup","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bcmd.2009.08.002","article-title":"The clinical course of untreated Gaucher disease in 22 patients over 10 years: haematological and skeletal manifestations","volume":"43","author":"Piran","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Spanish Group on Gaucher Disease. Quality of life to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual Life Res"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.10.015_bib36","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1259\/bjr.75.suppl_1.750037","article-title":"Bone complications in children with Gaucher disease","volume":"75","author":"Bembi","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","article-title":"Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience","volume":"30","author":"Sido","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib38","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajmg.a.32253","article-title":"The Erlenmeyer flask bone deformity in the skeletal dysplasias","volume":"149A","author":"Faden","year":"2009","journal-title":"Am J Med Gen A"},{"key":"10.1016\/j.berh.2011.10.015_bib39","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in Type 1 Gaucher disease","volume":"11","author":"Pastores","year":"1996","journal-title":"J Bone Min Res"},{"key":"10.1016\/j.berh.2011.10.015_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00269916","article-title":"An adult form of Gaucher\u2019s disease with a huge tumour formation of the right tibia","volume":"8","author":"Watanabe","year":"1984","journal-title":"Int Orthop"},{"key":"10.1016\/j.berh.2011.10.015_bib41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0720-048X(97)01158-3","article-title":"Pseudotumor formation in tibia in Gaucher\u2019s disease","volume":"26","author":"Ozturk","year":"1998","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02412357","article-title":"Extraosseous extension of Gaucher cell deposits mimicking malignancy","volume":"23","author":"Hermann","year":"1994","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s002560050003","article-title":"Type I Gaucher disease: extraosseous extension of skeletal disease","volume":"29","author":"Poll","year":"2000","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib44","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s003300000446","article-title":"Extraosseous manifestation of Gaucher\u2019s disease type I: MR and histological appearance","volume":"10","author":"Poll","year":"2000","journal-title":"Eur Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","article-title":"Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients","volume":"22","author":"Vom Dahl","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.10.015_bib46","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1259\/bjr.75.suppl_1.750013","article-title":"Imaging and quantifying skeletal involvement in Gaucher disease","volume":"75","author":"Maas","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1006\/bcmd.2001.0474","article-title":"Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease","volume":"27","author":"Hollak","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib48","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type 1 Gaucher\u2019s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.berh.2011.10.015_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging \u2013 initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.berh.2011.10.015_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejrad.2006.11.024","article-title":"S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease","volume":"52","author":"Roca","year":"2007","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib51","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","article-title":"Vertebral disc ration as a parameter for bone marrow involvement","volume":"26","author":"Vlieger","year":"2002","journal-title":"J Comput Assit Tomogr"},{"key":"10.1016\/j.berh.2011.10.015_bib52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","article-title":"Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results","volume":"30","author":"Poll","year":"2001","journal-title":"Skelet Radiol"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.10.015_bib53","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","article-title":"Response of Gaucher bone disease to enzyme replacement therapy","volume":"75","author":"Poll","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitive assessment of skeletal response to enzyme replacement therapy for Gaucher\u2019s disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.berh.2011.10.015_bib55","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project","volume":"94","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.berh.2011.10.015_bib56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Mass","year":"2008","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.berh.2011.10.015_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3413\/nukmed-0142","article-title":"Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease?","volume":"47","author":"Mikosch","year":"2008","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.berh.2011.10.015_bib58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00003072-199204000-00003","article-title":"Skeletal scintigraphy of pseudo-osteomyelitis in Gaucher\u2019s disease. Two case reports and a review of the literature","volume":"17","author":"Bilchik","year":"1992","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.berh.2011.10.015_bib59","first-page":"1253","article-title":"Severity of bone marrow involvement in patients with Gaucher\u2019s disease evaluated by scintigraphy with 99mTc-sestamibi","volume":"44","author":"Mariani","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.berh.2011.10.015_bib60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF01247378","article-title":"Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher\u2019s disease","volume":"23","author":"Mariani","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.berh.2011.10.015_bib61","series-title":"Gaucher disease","first-page":"283","article-title":"Radionuclide evaluation of Gaucher disease","author":"Mariani","year":"2007"},{"issue":"Suppl. 5","key":"10.1016\/j.berh.2011.10.015_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.berh.2011.10.015_bib63","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","article-title":"Gaucher disease \u2013 recommendations on diagnosis, evaluation and monitoring","volume":"158","author":"Charrow","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.berh.2011.10.015_bib64","unstructured":"Beck M, vom Dahl S, Mengel E, et\u00a0al. Leitlinie zu Morbus Gaucher. Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Speichererkrankungen in der Deutschen Gesellschaft f\u00fcr Kinder- und Jugendmedizin. Available from: www.aps-med.de."},{"key":"10.1016\/j.berh.2011.10.015_bib65","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/bmj.327.7413.462","article-title":"Treatment of lysosomal storage disorders","volume":"327","author":"Mehta","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2011.10.015_bib66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.berh.2011.10.015_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant resources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2011.10.015_bib68","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.berh.2011.10.015_bib69","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","article-title":"Individualised low-dose alglucerase therapy for type 1 Gaucher disease","volume":"345","author":"Hollak","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2011.10.015_bib70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","article-title":"Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months","volume":"82","author":"Pastores","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.berh.2011.10.015_bib71","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.berh.2011.10.015_bib72","first-page":"749","article-title":"Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI","volume":"144","author":"T\u00f3th","year":"2003","journal-title":"Orv Hetil"},{"key":"10.1016\/j.berh.2011.10.015_bib73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.berh.2011.10.015_bib74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2011.10.015_bib75","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.berh.2011.10.015_bib76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"21","author":"Wenstrup","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2011.10.015_bib77","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00774-004-0529-8","article-title":"Bone density changes with enzyme therapy in Gaucher disease","volume":"22","author":"Lebel","year":"2004","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.berh.2011.10.015_bib78","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(94)90462-6","article-title":"Enzyme replacement treatment in type 1 and type 3 Gaucher\u2019s disease","volume":"344","author":"Bembi","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2011.10.015_bib79","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.berh.2011.10.015_bib80","first-page":"703","article-title":"Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher\u2019s disease","volume":"91","author":"Giraldo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.berh.2011.10.015_bib81","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib82","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, non-comparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.berh.2011.10.015_bib83","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.berh.2011.10.015_bib84","doi-asserted-by":"crossref","unstructured":"Peterschmitt J, Lukina E, Watman NP, et\u00a0al. Genz-112638 for Gaucher disease type 1: phase 2 clinical trial results after 18 months of treatment. 51st ASH annual meeting and exposition, Abstract 1349. New Orleans; December 2009.","DOI":"10.1182\/blood.V114.22.1349.1349"},{"key":"10.1016\/j.berh.2011.10.015_bib85","first-page":"503","article-title":"Treatment of type 1 Gaucher\u2019s disease affecting bone with aminohydroxy propylidene bisphosphonate (pamidronate)","volume":"79","author":"Osterle","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.berh.2011.10.015_bib86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1542\/peds.94.3.385","article-title":"Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher\u2019s disease","volume":"94","author":"Samuel","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.berh.2011.10.015_bib87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.1994.tb12968.x","article-title":"Aminohydroxypropylidene-bisphosphonate in the treatment of bone lesions in a case of Gaucher\u2019s disease type 3","volume":"83","author":"Bembi","year":"1994","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.berh.2011.10.015_bib88","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM199709043371015","article-title":"Short-term effects of pamidronate in patients with Gaucher\u2019s disease and severe skeletal involvement","volume":"337","author":"Ciana","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2011.10.015_bib89","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.berh.2011.10.015_bib90","first-page":"37","article-title":"Orthopaedic manifestations of Gaucher disease","volume":"65","author":"Lutsky","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib91","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.lpm.2007.04.012","article-title":"Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment","volume":"36","author":"Javier","year":"2007","journal-title":"Presse Med"},{"key":"10.1016\/j.berh.2011.10.015_bib92","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/17453670902930032","article-title":"Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease","volume":"80","author":"Lebel","year":"2009","journal-title":"Acta Orthop"},{"key":"10.1016\/j.berh.2011.10.015_bib93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/145749690309200309","article-title":"Stability of internally fixed femoral neck fractures augmented with resorbable cement. A prospective randomized study using radiostereometry","volume":"92","author":"Mattsson","year":"2003","journal-title":"Scand J Surg"},{"key":"10.1016\/j.berh.2011.10.015_bib94","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2214\/AJR.07.3550","article-title":"Correlation of MRI-based bone marrow burden score with genotype and spleen status in Gaucher\u2019s disease","volume":"191","author":"DeMayo","year":"2008","journal-title":"AJR"},{"key":"10.1016\/j.berh.2011.10.015_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1005451300167","article-title":"Severe skeletal complications in Japanese patients with type 1 Gaucher disease","volume":"22","author":"Ida","year":"1999","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.berh.2011.10.015_bib96","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10354-010-0819-9","article-title":"Villa Metabolica \u2013 a center of excellence for the diagnosis and treatment of lysosomal storage disorders","volume":"160","author":"Beck","year":"2010","journal-title":"Wien Med Wschr"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694211000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694211000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:28:34Z","timestamp":1713198514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694211000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1521694211000908"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2011.10.015","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}